KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Cost of RevenueEBIATGross ProfitLeasesNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Novartis Ag (NVS) EBIAT (2016 - 2025)

Novartis Ag's EBIAT history spans 14 years, with the latest figure at $4.0 billion for Q2 2025.

  • On a quarterly basis, EBIAT rose 23.97% to $4.0 billion in Q2 2025 year-over-year; TTM through Jun 2025 was $17.8 billion, a 37.18% increase, with the full-year FY2025 number at $14.0 billion, up 16.99% from a year prior.
  • EBIAT hit $4.0 billion in Q2 2025 for Novartis Ag, down from $5.9 billion in the prior quarter.
  • Over the last five years, EBIAT for NVS hit a ceiling of $6.0 billion in Q2 2021 and a floor of $514.0 million in Q1 2021.
  • Historically, EBIAT has averaged $3.2 billion across 5 years, with a median of $4.0 billion in 2022.
  • Biggest five-year swings in EBIAT: skyrocketed 164.95% in 2021 and later decreased 29.6% in 2024.
  • Tracing NVS's EBIAT over 5 years: stood at $5.0 billion in 2021, then fell by 20.99% to $3.9 billion in 2022, then increased by 17.81% to $4.6 billion in 2023, then rose by 28.69% to $5.9 billion in 2024, then crashed by 32.19% to $4.0 billion in 2025.
  • Business Quant data shows EBIAT for NVS at $4.0 billion in Q2 2025, $5.9 billion in Q4 2024, and $3.2 billion in Q2 2024.